Fig 1: BMP5 contributes to reduce migration and invasion abilities of tumor cells. (A) Low BMP5 expression is associated with poor survival outcomes of breast cancer patients. (B) Patients with stage 3 disease showed higher BMP5 levels than those of stage 2 patients. (C,D) Migration/invasion abilities were decreased by treatment of recombinant BMP5; however, the capabilities were enhanced following BMP5 downregulation. p values were calculated using ANOVA. * p < 0.05, ** p < 0.01, **** p < 0.0001.
Fig 2: G9a knockdown facilitates Smad protein phosphorylation via BMP5 activation. (A,B) G9a-knockdown-induced increase in BMP5 expression had no effect on the total level of either Smad1 or Smad5. G9a knockdown increased phosphorylation of Smad1/5/9. (C) ICC demonstrated that nuclear translocation of pSmad1/5/9 was increased in G9a-depleted MCF7 cells. (D) Similar tendency was found after treatment of recombinant BMP5. p values were calculated using ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns = not significant.
Fig 3: G9a knockdown may lead to increase in BMP5 expression. (A) Regulatory factors suppressing tumor aggressiveness were identified by using microarray analysis. (B) Expression levels for each gene were compared (ratios between gene expression levels of non-silencing control). In two G9a knockdown cells (shG9a #1 and shG9a #2), expression levels for each gene were compared to those of non-silencing control. Then the most upregulated and downregulated genes were screened. (C) G9a knockdown cells showed increase in BMP5 expression. (D) Reduced G9a occupancy was found at the BMP5 promoter region. G9a knockdown cells also showed decreased H3K9me2 occupancy at the promoter region of BMP5. p values were calculated using ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Supplier Page from R&D Systems, a Bio-Techne Brand for Recombinant Human BMP-5 (CHO-expressed) Protein